Table 4.
Attrition rate of the first year in PLHIV who started ART between 2003 and June 2015 in Guangxi, China.
| Variable | Number | Attritions | Person-years | Attritions per 100 person-years (95% CI) | HR (95% CI) | P | AHR (95% CI) | P |
|---|---|---|---|---|---|---|---|---|
| Total | 58,115 | 8,947 | 51,066.90 | 17.52 (17.17-17.87) | — | — | — | — |
| Age (years) | ||||||||
| 18-34 | 18,358 | 2,424 | 16,591.47 | 14.61 (14.04-15.18) | Reference | Reference | ||
| 35-49 | 19,290 | 2,770 | 17,079.86 | 16.22 (15.63-16.81) | 1.11 (1.05-1.17) | <0.001 | 1.15 (1.09-1.22) | <0.001 |
| 50-70 | 17,457 | 2,958 | 15,016.71 | 19.7 (19.01-20.39) | 1.35 (1.28-1.42) | <0.001 | 1.55 (1.46-1.64) | <0.001 |
| ≥70 | 3,010 | 795 | 2,378.87 | 33.42 (31.15-35.68) | 2.27 (2.09-2.46) | <0.001 | 2.51 (2.30-2.73) | <0.001 |
| Sex | ||||||||
| Male | 38,957 | 6,284 | 33,799.71 | 18.59 (18.14-19.04) | Reference | Reference | ||
| Female | 19,158 | 2,663 | 17,267.19 | 15.42 (14.85-15.99) | 0.83 (0.79-0.87) | <0.001 | 0.89 (0.85-0.94) | <0.001 |
| Marital status | ||||||||
| Married or cohabitation | 40,224 | 5,697 | 35,698.49 | 15.96 (15.55-16.36) | Reference | Reference | ||
| Other | 17,891 | 3,250 | 15,368.41 | 21.15 (20.44-21.86) | 1.32 (1.27-1.38) | <0.001 | 1.32 (1.26-1.38) | <0.001 |
| Route of HIV transmission | ||||||||
| Heterosexual intercourse | 49,608 | 7,357 | 43,780.65 | 16.80 (16.43-17.18) | Reference | Reference | ||
| Intravenous drug use | 5,954 | 1,289 | 4,994.46 | 25.81 (24.43-27.18) | 1.53 (1.44-1.62) | <0.001 | 1.87 (1.75-2.00) | <0.001 |
| Homosexual intercourse | 925 | 66 | 866.24 | 7.62 (5.83-9.41) | 0.45 (0.36-0.58) | <0.001 | 0.45 (0.35-0.58) | <0.001 |
| Other | 1,628 | 235 | 1,425.56 | 16.48 (14.43-18.54) | 0.98 (0.86-1.12) | 0.783 | 1.08 (0.95-1.23) | 0.226 |
| CD4 cell count (cells/μL) before ART | ||||||||
| <200 | 34,774 | 5,030 | 30,201.91 | 16.65 (16.21-17.10) | Reference | Reference | ||
| 200-350 | 16,252 | 2,598 | 14,605.50 | 17.79 (17.12-18.45) | 1.07 (1.02-1.12) | 0.006 | 1.01 (0.96-1.06) | 0.765 |
| 350-500 | 4,550 | 783 | 4,076.29 | 19.21 (17.90-20.52) | 1.15 (1.07-1.24) | <0.001 | 1.11 (1.03-1.21) | 0.007 |
| ≥500 | 1,648 | 321 | 1,459.20 | 22.00 (19.65-24.34) | 1.32 (1.18-1.48) | <0.001 | 1.29 (1.15-1.45) | <0.001 |
| Missing | 891 | 215 | 724.00 | 29.70 (25.83-33.57) | 1.78 (1.55-2.04) | <0.001 | 1.62 (1.41-1.86) | <0.001 |
| Initial ART regimen | ||||||||
| The first-line ART containing D4T | 14,244 | 1,922 | 12,276.66 | 15.66 (14.97-16.34) | Reference | Reference | ||
| The first-line ART containing AZT | 23,059 | 3,845 | 20,389.98 | 18.86 (18.28-19.44) | 1.20 (1.14-1.27) | <0.001 | 1.09 (1.03-1.16) | 0.003 |
| The first-line ART containing TDF | 13,965 | 1,935 | 12,508.72 | 15.47 (14.80-16.14) | 0.99 (0.93-1.05) | 0.734 | 0.81 (0.75-0.87) | <0.001 |
| The first-line ART containing LPV/r | 4,510 | 1,004 | 3,765.83 | 26.66 (25.05-28.27) | 1.70 (1.57-1.83) | <0.001 | 1.34 (1.23-1.46) | <0.001 |
| Other | 2,337 | 241 | 2,125.71 | 11.34 (9.94-12.73) | 0.73 (0.64-0.83) | <0.001 | 0.87 (0.76-1.00) | 0.044 |
| Level of ART site | ||||||||
| Provincial | 10,920 | 1,470 | 9,810.33 | 14.98 (14.24-15.73) | Reference | Reference | ||
| Prefecture | 22,525 | 3,378 | 20,001.78 | 16.89 (16.33-17.44) | 1.13 (1.06-1.20) | <0.001 | 1.02 (0.96-1.08) | 0.593 |
| County | 24,670 | 4,099 | 21,254.79 | 19.29 (18.71-19.86) | 1.29 (1.21-1.36) | <0.001 | 1.04 (0.98-1.11) | 0.178 |
| Year of ART initiation | ||||||||
| 2003-2008 | 7,741 | 694 | 6,865.09 | 10.11 (9.38-10.84) | Reference | Reference | ||
| 2009-2011 | 17,800 | 2,813 | 15,542.50 | 18.1 (17.45-18.75) | 1.78 (1.64-1.93) | <0.001 | 1.74 (1.60-1.91) | <0.001 |
| 2012-2015 | 32,574 | 5,440 | 28,659.32 | 18.98 (18.49-19.47) | 1.87 (1.73-2.02) | <0.001 | 1.90 (1.73-2.08) | <0.001 |
ART: antiretroviral therapy; D4T: stavudine; AZT: azidothymidine; TDF: tenofovir; LPV/r: ritonavir-boosted lopinavir; HR: hazard ratio; AHR: adjusted hazard ratio.